Cargando…
Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug
Since 1985, the thiazolidinedione pioglitazone has been widely used as an insulin sensitizer drug for type 2 diabetes mellitus (T2DM). Although fluid retention was early recognized as a safety concern, data from clinical trials have not provided conclusive evidence for a benefit or a harm on cardiac...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130304/ https://www.ncbi.nlm.nih.gov/pubmed/34006325 http://dx.doi.org/10.1186/s12933-021-01294-7 |